EUCTR2004-004024-12-ATActive, not recruitingPhase 1
Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma - STOMOX II
Technical University of Munich0 sites0 target enrollmentStarted: October 14, 2005Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •histologically confirmed gastro-oesophageal adenocarcinoma
- •advanced disease (locally irresectable or metatstatic)
- •no systemic pretreatment, one neoadjuvant or adjuvant chemotherapy is acceptable (>6 month)
- •at least one unidimensional measurable cancer manifestation (>/= 1cm)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Second malignancy
- •Cardiac insufficiency, untreated ischemic heart disease
- •Uncontrolled Infection
- •Uncontrolled diabetes mellitus
Investigators
Similar Trials
Active, not recruiting
Phase 1
Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma - STOMOX IIadvanced gastro-oesophageal adenocarcinomaEUCTR2004-004024-12-DETechnical University of Munich
Unknown
Phase 2
EGFR Monoclonal Antibody for Advanced Gastric CancerCetuximabNimotuzumabGastric CancerNCT04136600Shanghai Changzheng Hospital100
Active, not recruiting
Not Applicable
Phase II study of cetuximab in combination with cisplatin-docetaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a biomarker-based assessment of activity. - NDon small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10001183MedDRA version: 9.1Level: LLTClassification code 10025038EUCTR2008-008387-27-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
Active, not recruiting
Not Applicable
Randomised phase II study of cetuximab in combination with gemcitabine or gemcitabine followed by cetuximab in patients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapyPatients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapy.MedDRA version: 6.1Level: PTClassification code 10061873EUCTR2004-002811-98-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE100
Active, not recruiting
Not Applicable
Study of the combination of gemcitabine, cetuximab and radiotherapy in patients with head and neck cancer - RAGEEUCTR2009-017943-32-BEAntwerp University Hospital25